CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| A011502 | Alliance | A Randomized Phase III Double Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial | Adult CIRB - Late Phase Emphasis | Available to Open |
| A091202 | Alliance | A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist; Efatutazone in Patients with Previously Treated; Unresectable Myxoid Liposarcoma | Adult CIRB - Early Phase Emphasis | Available to Open |
| A041702 | Alliance | A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) | Adult CIRB - Late Phase Emphasis | Available to Open |
| A051902 | Alliance | A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas | Adult CIRB - Late Phase Emphasis | Available to Open |
| A092107 | Alliance | A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma | Adult CIRB - Late Phase Emphasis | Available to Open |
| ABTC-1604 | Alliance | Phase 0/I Study of AMG 232 (KRT 232) Concentrations in Brain Tissue in Patients with Recurrent Glioblastoma and of AMG 232 (KRT 232) in Combination with Radiation in Patients with Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters | Adult CIRB - Late Phase Emphasis | Available to Open |
| A021804 | Alliance | A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma | Adult CIRB - Late Phase Emphasis | Available to Open |
| A022102 | Alliance | Randomized Phase III trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma | Adult CIRB - Late Phase Emphasis | Available to Open |
| A051301 | Alliance | A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype | Adult CIRB - Late Phase Emphasis | Available to Open |
| A032002 | Alliance | Phase II Randomized Trial of Atezolizumab versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART) | Adult CIRB - Late Phase Emphasis | Available to Open |